Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

4.37USD
3:37pm GMT
Change (% chg)

$-0.04 (-0.91%)
Prev Close
$4.41
Open
$4.38
Day's High
$4.38
Day's Low
$4.37
Volume
1,343
Avg. Vol
10,443
52-wk High
$11.20
52-wk Low
$3.20

Select another date:

Tue, Jan 16 2018

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH

BRIEF-RXi Pharmaceuticals Announces Reverse Stock Split

* RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10

BRIEF-RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

BRIEF-RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​

* RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​

BRIEF-RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights

* Reports third quarter 2017 financial results and recent corporate highlights

BRIEF-RXi Pharmaceuticals files for sale of up to 7.3 mln shares

* RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing‍​ Source text: (http://bit.ly/2vQLno4) Further company coverage:

Select another date: